Featured Research

from universities, journals, and other organizations

Newly discovered molecule could deliver drugs to treat diseases

Date:
September 24, 2012
Source:
Kansas State University
Summary:
Researchers have discovered a molecule that may be capable of delivering drugs inside the body to treat diseases.

Kansas State University researchers have discovered a molecule that may be capable of delivering drugs inside the body to treat diseases.

For the first time, researchers have designed and created a membrane-bounded vesicle formed entirely of peptides -- molecules made up of amino acids, the building blocks of protein. The membrane could serve as a new drug delivery system to safely treat cancer and neurodegenerative diseases.

A study led by John Tomich, professor of biochemistry at Kansas State University, has been published in the journal PLOS ONE in September, and a patent for the discovery is pending.

The peptides are a set of self-assembling branched molecules made up of naturally occurring amino acids. The chemical properties of a peptide create a vesicle that Tomich describes as a bubble: It's made up of a thin membrane and is hollow inside. Created in a water solution, the bubble is filled with water rather than air.

The peptides -- or bubbles -- can be made in a solution containing a drug or other molecule that becomes encapsulated as the peptide assembles, yielding a trapped compound, much like a gelatin capsule holds over-the-counter oral remedies. The peptide vesicles could be delivered to appropriate cells in the body to treat diseases and minimize potential side effects.

"We see this as a new way to deliver any kind of molecule to cells," Tomich said. "We know that in certain diseases subpopulations of cells have gone awry, and we'd like to be able to specifically target them instead of attacking every cell, including healthy ones."

The finding could improve gene therapy, which has the potential to cure diseases by replacing diseased cells with healthy ones. Gene therapy is being tested in clinical trials, but the biggest challenge is how best to deliver the genes.

Methods include cells with a virus being injected into the body, and liposomes -- fatty compounds -- carrying the genes. However, these methods may present some problems.

When a virus is used, the body's immune system can attack the virus or cause a tumor. Lipid-based systems may cause inflammation and may not properly bind to cells.

The peptides created by Kansas State University researchers have advantages over their lipid counterparts. The peptides have improved stability and durability, are easier and quicker to create, and they could be delivered to a specific area in the body.

The peptides can be designed to have the ability to target cells, tissues, tumors or organs, and to encapsulate chemical reagents, antibodies, toxins and inhibitors, Tomich said.

"We don't even begin to know all of the potential applications for this discovery," he said. "We envision that many products could be packaged and delivered using these peptides."

Partial funding for the study came from the Kansas State University Johnson Cancer Research Center, National Institutes of Health and Japan Society for the Promotion of Science.

Kansas State University collaborators include Sushanth Gudlur, May 2012 doctoral graduate in biochemistry, who first published the results in a dissertation; Pinakin Sukthankar, doctoral student in biochemistry; Jian Gao, former postdoctoral fellow in the department of biochemistry; Luz Adriana Avila Flores, graduate research assistant in the department of biochemistry; Yasuaki Hiromasa, research assistant professor of biochemistry; and Jianhan Chen, assistant professor of biochemistry. Takeo Iwamoto from the Jikei University School of Medicine in Japan also was a collaborator.


Story Source:

The above story is based on materials provided by Kansas State University. The original article was written by Trevor Davis. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sushanth Gudlur, Pinakin Sukthankar, Jian Gao, L. Adriana Avila, Yasuaki Hiromasa, Jianhan Chen, Takeo Iwamoto, John M. Tomich. Peptide Nanovesicles Formed by the Self-Assembly of Branched Amphiphilic Peptides. PLoS ONE, 2012; 7 (9): e45374 DOI: 10.1371/journal.pone.0045374

Cite This Page:

Kansas State University. "Newly discovered molecule could deliver drugs to treat diseases." ScienceDaily. ScienceDaily, 24 September 2012. <www.sciencedaily.com/releases/2012/09/120924142613.htm>.
Kansas State University. (2012, September 24). Newly discovered molecule could deliver drugs to treat diseases. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/09/120924142613.htm
Kansas State University. "Newly discovered molecule could deliver drugs to treat diseases." ScienceDaily. www.sciencedaily.com/releases/2012/09/120924142613.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins